KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Gains from Investment Securities: 2017-2024

Historic Gains from Investment Securities for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $1.1 million.

  • Aquestive Therapeutics' Gains from Investment Securities fell 65.35% to $70,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $793,000, marking a year-over-year decrease of 25.54%. This contributed to the annual value of $1.1 million for FY2024, which is 439.71% up from last year.
  • Aquestive Therapeutics' Gains from Investment Securities amounted to $1.1 million in FY2024, which was up 439.71% from $204,000 recorded in FY2023.
  • Aquestive Therapeutics' Gains from Investment Securities' 5-year high stood at $1.1 million during FY2024, with a 5-year trough of $52,000 in FY2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $204,000 (2023), whereas its average is $452,333.
  • As far as peak fluctuations go, Aquestive Therapeutics' Gains from Investment Securities slumped by 82.61% in 2022, and later skyrocketed by 439.71% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Gains from Investment Securities stood at $700,000 in 2020, then crashed by 57.29% to $299,000 in 2021, then crashed by 82.61% to $52,000 in 2022, then spiked by 292.31% to $204,000 in 2023, then soared by 439.71% to $1.1 million in 2024.